Current Hematologic Malignancy Reports

, Volume 6, Issue 1, pp 36–46 | Cite as

What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?

  • Xavier C. BadouxEmail author
  • Michael J. Keating
  • William G. Wierda


Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with significant variation in disease progression, response to therapy, and survival outcome. Deletions of 17p or mutations of TP53 have been identified as one of the poorest prognostic factors, being predictive of short time for disease progression, lack of response to therapy, short response duration, and short overall survival. The treatment of patients with CLL has improved significantly with the development of chemoimmunotherapy, but this benefit was not pronounced in patients with 17p deletion. We compare various treatment strategies used in these patients, including FCR-like chemoimmunotherapy, alemtuzumab, other antibody combinations, or novel targeted therapies with promising results. Allogeneic stem cell transplantation offers the possibility for long-term disease control in these patients and should be considered early in younger, transplant-eligible patients. The current state of therapy is far from optimal and resources should be applied to studying therapeutic options for patients who have CLL with loss of p53 function.


Chronic lymphocytic leukemia p53 TP53 Frontline treatment del(17p) Prognosis Alemtuzumab Combination therapies Allogeneic stem cell transplantation AlloSCT 



Conflicts of interest: X.C. Badoux: None. M.J. Keating: Consultant for Roche, Celgene, GlaxoSmithKline, Genzyme. W.G. Wierda: Consultant, speaker, DSMB member for Genentech; speaker for Roche; speaker and consultant for Genzyme, Celgene, and Cephalon; speaker, research funding from GlaxoSmithKline.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Tam CS and Keating MJ: Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 2010, 7:521–532. This is a thorough review of chemoimmunotherapy in CLL.CrossRefPubMedGoogle Scholar
  2. 2.
    •• Hallek M, Fischer K, Fingerle-Rowson G, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164–1174. This publication demonstrates the survival advantage gained by adding rituximab to fludarabine and cyclophosphamide in this important phase III study in untreated patients with CLL. In addition, the study confirms the inferior response and outcomes experienced by patients with 17p deletions. CrossRefPubMedGoogle Scholar
  3. 3.
    • Tam CS, O’Brien S, Wierda W, et al.: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975–980. This article reports long-term results of the initial study of frontline FCR in patients with CLL. CrossRefPubMedGoogle Scholar
  4. 4.
    Isobe M, Emanuel BS, Givol D, et al.: Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986, 320:84–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Hollstein M, Sidransky D, Vogelstein B, et al.: p53 mutations in human cancers. Science 1991, 253:49–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323–331.CrossRefPubMedGoogle Scholar
  7. 7.
    Efeyan A and Serrano M: p53: guardian of the genome and policeman of the oncogenes. Cell cycle 2007, 6:1006–1010.PubMedGoogle Scholar
  8. 8.
    Seiler T, Dohner H and Stilgenbauer S: Risk stratification in chronic lymphocytic leukemia. Semin Oncol 2006, 33:186–194.CrossRefPubMedGoogle Scholar
  9. 9.
    Bates S, Phillips AC, Clark PA, et al.: p14ARF links the tumour suppressors RB and p53. Nature 1998, 395:124–125.CrossRefPubMedGoogle Scholar
  10. 10.
    Haines DS: The mdm2 proto-oncogene. Leuk Lymphoma 1997, 26:227–238.PubMedGoogle Scholar
  11. 11.
    Marine JC and Lozano G: Mdm2-mediated ubiquitylation: p53 and beyond. Cell death and differentiation 2010, 17:93–102.CrossRefPubMedGoogle Scholar
  12. 12.
    Watanabe T, Hotta T, Ichikawa A, et al.: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994, 84:3158–3165.PubMedGoogle Scholar
  13. 13.
    Bixby D, Kujawski L, Wang S, et al.: The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell cycle 2008, 7:971–979.PubMedGoogle Scholar
  14. 14.
    Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899–2908.CrossRefPubMedGoogle Scholar
  15. 15.
    Miyashita T, Krajewski S, Krajewska M, et al.: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9:1799–1805.PubMedGoogle Scholar
  16. 16.
    Thomas A, El Rouby S, Reed JC, et al.: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996, 12:1055–1062.PubMedGoogle Scholar
  17. 17.
    Johnston JB, Daeninck P, Verburg L, et al.: P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997, 26:435–449.PubMedGoogle Scholar
  18. 18.
    Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910–1916.CrossRefPubMedGoogle Scholar
  19. 19.
    Han T, Ozer H, Sadamori N, et al.: Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. N Engl J Med 1984, 310:288–292.CrossRefPubMedGoogle Scholar
  20. 20.
    Juliusson G and Gahrton G: Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. Cancer Genet Cytogenet 1990, 45:143–160.CrossRefPubMedGoogle Scholar
  21. 21.
    Juliusson G, Oscier D, Juliusson G, et al.: Cytogenetic findings and survival in B-cell chronic lymphocytic leukemia. Second IWCCLL compilation of data on 662 patients. Leukemia Lymphoma 1991, 5:21–25.CrossRefGoogle Scholar
  22. 22.
    Oscier DG, Stevens J, Hamblin TJ, et al.: Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol 1990, 76:352–358.CrossRefPubMedGoogle Scholar
  23. 23.
    Pittman S and Catovsky D: Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia. Br J Haematol 1984, 58:649–660.CrossRefPubMedGoogle Scholar
  24. 24.
    Geisler CH, Philip P, Christensen BE, et al.: In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997, 21:1011–1023.CrossRefPubMedGoogle Scholar
  25. 25.
    Fenaux P, Preudhomme C, Lai JL, et al.: Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992, 6:246–250.PubMedGoogle Scholar
  26. 26.
    Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15:995–1004.CrossRefPubMedGoogle Scholar
  27. 27.
    Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473–4479.CrossRefPubMedGoogle Scholar
  28. 28.
    • Butler T and Gribben JG: Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. Blood reviews 2010, 24:135–141. This is an up-to-date review of the utility of molecular profiling in CLL, including the roles of prognostic factors in developing risk-stratified therapy. CrossRefPubMedGoogle Scholar
  29. 29.
    Dal-Bo M, Bertoni F, Forconi F, et al.: Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Translational Med 2009, 7:76.CrossRefGoogle Scholar
  30. 30.
    • Tam CS, Shanafelt TD, Wierda WG, et al.: De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009, 114:957–964. This study demonstrates that patients with 17p deletion identified at diagnosis may have heterogenous prognosis, which may be dissected according to other clinical predictors, including IGHV mutational status, Rai stage, and percentage of cells with 17p deletions by FISH.CrossRefPubMedGoogle Scholar
  31. 31.
    Zenz T, Krober A, Scherer K, et al.: Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008, 112:3322–3329.CrossRefPubMedGoogle Scholar
  32. 32.
    Best OG, Gardiner AC, Davis ZA, et al.: A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia 2009, 23:212–214.CrossRefPubMedGoogle Scholar
  33. 33.
    •• Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446–5456. These updated guidelines on the management of CLL include indications for initial therapy. CrossRefPubMedGoogle Scholar
  34. 34.
    Dohner H, Fischer K, Bentz M, et al.: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995, 85:1580–1589.PubMedGoogle Scholar
  35. 35.
    el Rouby S, Thomas A, Costin D, et al.: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993, 82:3452–3459.PubMedGoogle Scholar
  36. 36.
    Pettitt AR, Clarke AR, Cawley JC, et al.: Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. Br J Haematol 1999, 105:986–988.CrossRefPubMedGoogle Scholar
  37. 37.
    Pettitt AR, Sherrington PD and Cawley JC: The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol 1999, 106:1049–1051.CrossRefPubMedGoogle Scholar
  38. 38.
    Silber R, Degar B, Costin D, et al.: Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 1994, 84:3440–3446.PubMedGoogle Scholar
  39. 39.
    Begleiter A, Mowat M, Israels LG, et al.: Chlorambucil in chronic lymphocytic leukemia: mechanism of action. Leuk Lymphoma 1996, 23:187–201.CrossRefPubMedGoogle Scholar
  40. 40.
    Hillmen P, Skotnicki AB, Robak T, et al.: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616–5623.CrossRefPubMedGoogle Scholar
  41. 41.
    Oscier DG, Wade R, Orchard J, et al.: Prognostic Factors in the UK LRF CLL4 Trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:299.Google Scholar
  42. 42.
    Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230–239.CrossRefPubMedGoogle Scholar
  43. 43.
    Flinn IW, Neuberg DS, Grever MR, et al.: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007, 25:793–798.CrossRefPubMedGoogle Scholar
  44. 44.
    Stilgenbauer S, Eichhorst BF, Busch R, et al.: Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC)—Comprehensive Analysis of the CLL4 Trial of the GCLLSG. ASH Annual Meeting Abstracts 2008, 112:2089.Google Scholar
  45. 45.
    Byrd JC, Gribben JG, Peterson BL, et al.: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006, 24:437–443.CrossRefPubMedGoogle Scholar
  46. 46.
    Kay NE, Wu W, Kabat B, et al.: Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 2010, 116:2180–2187.PubMedGoogle Scholar
  47. 47.
    Fischer K, Cramer P, Stilgenbauer S, et al.: Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract]. ASH Annual Meeting Abstracts 2009, 114:205.Google Scholar
  48. 48.
    Bosch F, Abrisqueta P, Villamor N, et al.: Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4578–4584.CrossRefPubMedGoogle Scholar
  49. 49.
    Faderl S, Wierda W, O’Brien S, et al.: Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leuk Res 2010, 34:284–288.CrossRefPubMedGoogle Scholar
  50. 50.
    Kay NE, Geyer SM, Call TG, et al.: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007, 109:405–411.CrossRefPubMedGoogle Scholar
  51. 51.
    Wierda WG, Kipps TJ, Durig J, et al.: Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial [abstract]. ASH Annual Meeting Abstracts 2009, 114:207.Google Scholar
  52. 52.
    Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554–3561.CrossRefPubMedGoogle Scholar
  53. 53.
    Lozanski G, Heerema NA, Flinn IW, et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278–3281.CrossRefPubMedGoogle Scholar
  54. 54.
    Osuji NC, Del Giudice I, Matutes E, et al.: The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005, 90:1435–1436.PubMedGoogle Scholar
  55. 55.
    Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768–773.CrossRefPubMedGoogle Scholar
  56. 56.
    Osterborg A, Fassas AS, Anagnostopoulos A, et al.: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996, 93:151–153.CrossRefPubMedGoogle Scholar
  57. 57.
    Mauro FR, Cortelezzi A, Molica S, et al.: Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study. ASH Annual Meeting Abstracts 2008, 112:3167.Google Scholar
  58. 58.
    Parikh SA, Keating M, O’Brien S, et al.: Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 2009, 114:208.Google Scholar
  59. 59.
    Dyer MJ, Kelsey SM, Mackay HJ, et al.: In vivo ‘purging’ of residual disease in CLL with Campath-1H. Br J Haematol 1997, 97:669–672.CrossRefPubMedGoogle Scholar
  60. 60.
    O’Brien SM, Kantarjian HM, Thomas DA, et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98:2657–2663.CrossRefPubMedGoogle Scholar
  61. 61.
    Thieblemont C, Bouafia F, Hornez E, et al.: Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004, 45:711–714.CrossRefPubMedGoogle Scholar
  62. 62.
    Wierda WG, Kipps TJ, Keating MJ, et al.: Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2010,Google Scholar
  63. 63.
    Byrd JC, Peterson BL, Rai KR, et al.: Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma 2009, 50:1589–1596.CrossRefPubMedGoogle Scholar
  64. 64.
    Hainsworth JD, Vazquez ER, Spigel DR, et al.: Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008, 112:1288–1295.CrossRefPubMedGoogle Scholar
  65. 65.
    Lin TS, Donohue KA, Byrd JC, et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010;28(29):4500–4506.CrossRefPubMedGoogle Scholar
  66. 66.
    Montillo M, Tedeschi A, Miqueleiz S, et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006, 24:2337–2342.CrossRefPubMedGoogle Scholar
  67. 67.
    Schweighofer CD, Ritgen M, Eichhorst BF, et al.: Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol 2009, 144:95–98.CrossRefPubMedGoogle Scholar
  68. 68.
    Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2008;112:119–128.CrossRefPubMedGoogle Scholar
  69. 69.
    Thornton PD, Matutes E, Bosanquet AG, et al.: High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003, 82:759–765.CrossRefPubMedGoogle Scholar
  70. 70.
    Castro JE, James DF, Sandoval-Sus JD, et al.: Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009, 23:1779–1789.CrossRefPubMedGoogle Scholar
  71. 71.
    Bowen DA, Call TG, Jenkins GD, et al.: Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007, 48:2412–2417.CrossRefPubMedGoogle Scholar
  72. 72.
    Pettitt R, Matutes E, Dearden C, et al.: Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL. Haematologica 2009, 94[suppl.2]:abs. 0351.Google Scholar
  73. 73.
    Stilgenbauer S, Cymbalista F, Leblond V, et al. Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine - Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW. ASH Annual Meeting Abstracts 2010, 116(21):920.Google Scholar
  74. 74.
    Zent CS, Call TG, Shanafelt TD, et al.: Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008, 113:2110–2118.CrossRefPubMedGoogle Scholar
  75. 75.
    Frankfurt O, Hamilton E, Duffey S, et al.: Alemtuzumab and Rituximab Combination Therapy for Patients with Untreated CLL—a Phase II Trial. ASH Annual Meeting Abstracts 2008, 112:2098.Google Scholar
  76. 76.
    Badoux X, Wierda WG, O’Brien SM, et al.: A phase II study of lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia. J Clin Oncol 2010, 28:abstr 6508.Google Scholar
  77. 77.
    Dreger P, Corradini P, Kimby E, et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12–17.CrossRefPubMedGoogle Scholar
  78. 78.
    Dreger P: Allotransplantation for chronic lymphocytic leukemia. Hematology 2009, 2009:602–609.CrossRefGoogle Scholar
  79. 79.
    Badoux XC, Keating M, O’Brien S, et al.: Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. ASH Annual Meeting Abstracts 2009, 114:1248.Google Scholar
  80. 80.
    • Schetelig J, van Biezen A, Brand R, et al.: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008, 26:5094–5100. The retrospective analysis of the EBMT registry data demonstrates the disease-free survival outcomes of patients with CLL after allogeneic stem cell transplantation. The survival of patients with 17p deletions is equivalent to those without deletions. CrossRefPubMedGoogle Scholar
  81. 81.
    • Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116(14):2438–2447. These are results of a prospective trial of allogeneic stem cell transplantation in CLL, demonstrating the equivalent activity of transplantation (EFS) in patients with or without 17p deletion. CrossRefPubMedGoogle Scholar
  82. 82.
    Christian BA, Grever MR, Byrd JC, et al.: Flavopiridol in chronic lymphocytic leukemia: a concise review. Clin Lymphoma Myeloma 2009, 9 Suppl 3:S179–185.PubMedGoogle Scholar
  83. 83.
    Lin TS, Ruppert AS, Johnson AJ, et al.: Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009, 27:6012–6018.CrossRefPubMedGoogle Scholar
  84. 84.
    Lin TS, Blum KA, Fischer DB, et al.: Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010, 28:418–423.CrossRefPubMedGoogle Scholar
  85. 85.
    Andritsos L, Furman R, Flinn IW, et al.: A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:3017.Google Scholar
  86. 86.
    Robak T, Jamroziak K, Gora-Tybor J, et al.: Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010, 28:1863–1869.CrossRefPubMedGoogle Scholar
  87. 87.
    Bosch F, Ferrer A, Villamor N, et al.: Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008, 14:155–161.CrossRefPubMedGoogle Scholar
  88. 88.
    Eichhorst BF, Busch R, Stilgenbauer S, et al.: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382–3391.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Xavier C. Badoux
    • 1
    Email author
  • Michael J. Keating
    • 1
  • William G. Wierda
    • 1
  1. 1.Department of LeukemiaUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations